What question did this study set out to answer?

To determine whether 3 years of adjuvant oral clodronate therapy prevents the development of bone metastases in patients with primary node-positive breast cancer.

January 1, 2001Journal of Clinical Oncology

Adjuvant Clodronate Treatment Does Not Reduce the Frequency of Skeletal Metastases in Node-Positive Breast Cancer Patients: 5-Year Results of a Randomized Controlled Trial

View Full Paper

Ask AI

Bookmark

Authors

TSTiina SaartoUniversity of Helsinki CBCarl BlomqvistUniversity of Helsinki PVPekka VirkkunenHelsinki University Hospital

Discussion

Member takes

Implication

Randomized trial finds no bone metastasis prevention with adjuvant clodronate in node-positive breast cancer, indicating worse overall outcomes.

Key Points

To determine whether 3 years of adjuvant oral clodronate therapy prevents the development of bone metastases in patients with primary node-positive breast cancer.
A randomized controlled trial enrolled 299 women with primary node-positive breast cancer (282 analyzed) randomized to oral clodronate 1,600 mg daily (n = 149) or control (n = 150) for 3 years alongside standard adjuvant chemotherapy or endocrine therapy.
Patients were monitored over a 5-year follow-up period, evaluating bone recurrence, nonskeletal recurrence, disease-free survival (DFS), and overall survival (OS) using intent-to-treat and multivariate analyses.
Bone metastases occurred at similar rates between arms, detected in 29 patients (21%) in the clodronate group versus 24 patients (17%) in the control group (P = .27).
Nonskeletal recurrence was significantly higher with clodronate compared to control (60 patients [43%] vs. 36 patients [25%], P = .0007).
Clodronate treatment significantly reduced overall survival (70% vs. 83%, P = .009) and disease-free survival (56% vs. 71%, P = .007; multivariate DFS P = .009).

Cite This Study

Saarto et al. (2001) studied this question.

synapsesocial.com/papers/6a7071beac440176ef291bd1 https://doi.org/10.1200/jco.2001.19.1.10

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial finds no bone metastasis prevention with adjuvant clodronate in node-positive breast cancer, indicating worse overall outcomes.

Adjuvant Clodronate Treatment Does Not Reduce the Frequency of Skeletal Metastases in Node-Positive Breast Cancer Patients: 5-Year Results of a Randomized Controlled Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Adjuvant Clodronate Treatment Does Not Reduce the Frequency of Skeletal Metastases in Node-Positive Breast Cancer Patients: 5-Year Results of a Randomized Controlled Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider